Dr. Sallie Permar and her colleagues at Weill Cornell Medicine issued an urgent call to action this May: protect the institutions that have saved an estimated 154 million lives over the past fifty years, or risk losing them entirely. The vaccine research infrastructure they're fighting for is now under siege—not from disease, but from shifting priorities, eroded funding, and a crisis of public trust that threatens to hollow out the very scientific enterprise that brought us smallpox eradication and, more recently, the rapid development of COVID-19 vaccines.
The stakes could hardly be higher. The commentary, published May 22 in Nature Microbiology and co-authored by Dr. Cassandra Simonich at the University of Washington and Ilina Das Ewen at Weill Cornell, arrives at a moment when declining routine immunization rates and rising measles outbreaks are colliding with growing distrust in science itself. Cuts to federal funding and the dismantling of training programs in immunology, microbiology and public health at American universities are thinning the pipeline of new vaccine scientists at precisely the moment when the world needs them most. Recent outbreaks—hantavirus on a cruise ship, Ebola in West Africa—have already reached American shores, a sobering reminder of how quickly diseases cross borders.
The global consequences of American withdrawal from vaccine infrastructure are staggering. If the U.S. follows through on its withdrawal from the World Health Organization and its long-term partnership with Gavi, the Vaccine Alliance, the result could be 75 million fewer children vaccinated and 1.2 million preventable deaths worldwide. These are not abstract numbers; they represent children whose lives hang in the balance, communities left vulnerable, and the reversal of hard-won gains built by generations of scientists.
Yet the commentary offers something beyond alarm: a roadmap for scientists to reclaim their voice and rebuild public understanding. Dr. Permar emphasizes that researchers must "communicate with the public in ways we never did before, in order to create an understanding of the value of vaccines and protect the infrastructure that keeps us safe." The authors suggest concrete actions—engagement with policymakers, social media campaigns, training workshops—but also something more personal: sharing stories about real-world vaccine impact through written commentary, explanatory videos, and community speaking. Das Ewen notes that "working with journalists ensures accurate coverage and helps rebuild public trust," recognizing that the fight for vaccine research is fundamentally a fight for how science is heard and believed.
The investments being protected are not merely academic. The mRNA technology developed for vaccines may unlock new therapies for cancer and autoimmune diseases. Decades of scientific collaboration have produced breakthroughs that ripple across medicine and public health. But this progress depends on what seems almost antique in an era of quick wins: steady funding, support for young researchers, and global partnerships that span continents and generations.
"It is our turn to step up and protect the hard-won gains made by our predecessors," Dr. Permar said. In that sentence lies both accountability and possibility—a reminder that vaccine scientists didn't inherit a protected world, but rather built one through persistent effort and advocacy. Now, they must do it again, this time in full public view.